Tricyclic Antidepressants Confirmation, Urine (Pain Management)
Use
Drug analysis/clinical drug monitoring
Special Instructions
This assay is specifically intended for pain management and should not be used for workplace testing or state regulatory workplace testing programs. The test results should be interpreted in the context of clinical information, considering patient metabolic variables, specific drug chemistry, and specimen characteristics. Technical consultation is available if there is a discrepancy between test results and expected clinical outcomes.
Limitations
The Tricyclic Antidepressants Confirmation test is not cleared or approved by the FDA. The performance characteristics of this test were determined by Labcorp. Cross-reactivity may occur, especially with similar-structured compounds like Cyclobenzaprine, which, although included due to its structural similarity to TCAs, acts as a skeletal muscle relaxant rather than an antidepressant. Test interpretation requires careful consideration of the clinical context.
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 19315-1
- 19315-1
- 16225-5
- 20515-3
- 45144-3
- 3492-6
- 61409-9
- 61410-7
- 61415-6
- 58014-2
- 12386-9
- 4084-0
- 12443-8
- 4001-4
- 26978-7
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
20 mL
Minimum Volume
7 mL
Container
Plastic urine container
Storage Instructions
Maintain specimen at room temperature. Stability: If arrival at lab will extend beyond seven days then refrigerate.
Other tests from different labs that may be relevant